請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61575
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華(Jih-Hwa Guh) | |
dc.contributor.author | Wohn-Jenn Leu | en |
dc.contributor.author | 呂婉禎 | zh_TW |
dc.date.accessioned | 2021-06-16T13:06:17Z | - |
dc.date.available | 2023-08-01 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-02 | |
dc.identifier.citation | (1) Prostate cancer. American cancer society 2013.
(2) Cancer Facts & Figures 2013. Atlanta, Ga:American cancer society 2013. (3) Kuo YJ, Lin SF, Chang YH, Pan CC. Trends in prostate needle biopsy diagnosis. A ten year experience of a medical center in Taiwan. Pathology International 62:191-8 (2012) (4) Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia 12:685-96 (2012) (5) Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215–1223 (1997) (6) Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero,et al. The LNCaP cell line: A new model for studies on human prostatic carcinoma. Progress in Clinical Biological Research .37:115–132 (1980) (7) Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investigative urology 17:16–23 (1979) (8) Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). International Journal of Cancer 21:274–281 (1978) (9) Russell PJ, Kingsley EA. Human prostate cancer cell lines. Methods in Molecular Medicine 81:21-39 (2003) (10) Skou JC. The Identification of the Sodium-Potassium Pump. Bioscience Reports 24:436-51 (2004) (11) Toyoshima C, Kanai R, Cornelius F. First crystal structures of Na/K-ATPase: new light on the oldest ion pump. Structure 19:1732-8 (2011) (12) Horisberger JD. Recent insights into the structure and mechanism of the sodium pump. Physiology (Bethesda) 19:377-87 (2004) (13) Katz AM. Physiology of the Heart. Fifth ed. Lippincott Williams & Wilkins, a WOLTERS KLUWER business, Philadelphia, PA, 2011. (14) Aperia, A. New roles for an old enzyme: Na, K-ATPase emerges as an interesting drug target. Journal of Internal Medicine 261:44–52 (2007). (15) Tian, J., Cai, T., Yuan, Z., Wang, H., Liu, L., Haas, M., Maksimova, E.,Huang, X. Y., and Xie, Z. J. Binding of Src to Na/K-ATPase Forms a Functional Signaling Complex. Molecular Biology of the Cell 17:317–326 (2006) (16) Bundgaard H, Kjeldsen K. Human myocardial Na/K-ATPase concentration in heart failure. Molecular and Cellular Biochemistry 163-164:277-83 (1996) (17) Li Z, Zhang Z, Xie JX, Li X, Tian J, Cai T, Cui H, Ding H, Shapiro JI, Xie Z. Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cells The Journal of Biological Chemistry 286:32394-403 (2011) (18) Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nature Reviews Drug Discovery 7:926-35 (2008) (19) Melero, C. P., Medardea, M. & Feliciano, A. S. A short review on cardiotonic steroids and their aminoguanidine analogues. Molecules. 5:51–81 (2000). (20) Rathore H, From AH, Ahmed K, Fullerton DS. Cardiac glycosides. 7. Sugar stereochemistry and cardiac glycoside activity. Journal of Medicinal Chemistry 29:1945-52 (1986) (21) Proppe D. Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs. Clinical and Experimental Pharmacology and Physiology. 2:489-502 (1975) (22) Erdmann E, Schoner W. Ouabain-receptor interactions in (Na+K+)-ATPase preparations from different tissues and species. Determination of kinetic constants and dissociation constants. Biochimica et Biophysica Acta 307: 386–98 (1973) (23) Sibarov DA, Bolshakov AE, Abushik PA, Krivoi II, Antonov SM. Na+,K+-ATPase functionally interacts with the plasma membrane Na+,Ca2+ exchanger to prevent Ca2+ overload and neuronal apoptosis in excitotoxic stress. Journal of Pharmacology and Experimental Therapeutics 343:596-607 (2012) (24) Lingrel JB. The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase. Annual Review of Physiology 72:395-412 (2010) (25) Dong XH, Komiyama Y, Nishimura N, Masuda M, Takahashi H. Nanomolar level of ouabain increases intracellular calcium to produce nitric oxide in rat aortic endothelial cells. Clinical and Experimental Pharmacology and Physiology 31:276–283 (2004) (26) Huang L, Li H, Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. Journal of Molecular and Cellular Cardiology 29:429–437 (1997) (27) Tian J, Cai T, Yuan Z, Wang H, Liu L, Haas M, Maksimova E, Huang XY, Xie ZJ. Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Molecular Biology of the Cell 17:317–326 (2006) (28) Chang HS, Chiang MY, Hsu HY, Yang CW, Lin CH, Lee SJ, Chen IS. Cytotoxic cardenolide glycosides from the root of Reevesia formosana. Phytochemistry 87:86-95 (2013) (29) Noteborn MH. Apoptin-induced apoptosis: a review. Apoptosis. 4:317-9 (1999) (30) Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415-20 (1994) (31) Wyllie AH, Beattie GJ, Hargreaves AD. Chromatin changes in apoptosis. Histochemical Journal 13:681-92 (1981) (32) Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC, Kroemer G. Two distinct pathways leading to nuclear apoptosis. The Journal of Experimental Medicine 192:571-80 (2000) (33) MacFarlane M. Cell death pathways--potential therapeutic targets. Xenobiotica 39:616-24 (2009) (34) Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treatment Reviews 38:868-76 (2012) (35) Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 4:330-49 (2012) (36) Spencer ML, Theodosiou M, Noonan DJ. NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif. The Journal of Biological Chemistry 279:37069-78 (2004) (37) Gunbin KV, Suslov VV, Turnaev II, Afonnikov DA, Kolchanov NA. Molecular evolution of cyclin proteins in animals and fungi. BMC Evolutionary Biology 28;11:224 (2011) (38) Carnero A. Targeting the cell cycle for cancer therapy. British Journal of Cancer 87:129-33 (2002) (39) Leake R. The cell cycle and regulation of cancer cell growth. Annals of the New York Academy of Sciences 784:252-62 (1996) (40) Muşat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, Grossman AB. Cell cycle dysregulation in pituitary oncogenesis. Frontiers of Hormone Research 32:34-62 (2004) (41) Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica 97:1736-42 (2012) (42) Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Research 13:R80 (2011) (43) Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Annals of the New York Academy of Sciences 1171:242-9 (2007) (44) Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145:5439-47 (2004) (45) Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL, Levy J, Sharoni Y. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. European Journal of Nutrition 45:275-82 (2006) (46) Lee CH, Hung HW, Hung PH, Shieh YS. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Molecular Cancer 9:64 (2010) (47) Takemaru KI, Moon RT. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. The Journal of Biological Chemistry 149:249-54 (2002) (48) Yamazaki K, Hanami K, Nagao T, Asoh A, Sugano I, Ishida Y. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear b catenin accumulation and k-ras gene mutation. Molecular Pathology 56:336-41 (2003) (49) Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. The EMBO Journal 18:1571-83 (1999) (50) Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular Cancer 6:24 (2007) (51) Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes & Development 12:3499–3511 (1998) (52) Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes & Development 11:957–972 (1997) (53) Germain D, Russell A, Thompson A, Hendley J. Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. The Journal of Biological Chemistry 275:12074–79 (2000) (54) Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. The Journal of Biological Chemistry 279:41504–11 (2004) (55) Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, Bachs O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. The Journal of Biological Chemistry 275:35091–97 (2000) (56) Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annual Review of Biochemistry 67:545-79 (1998) (57) Kouzarides T. Chromatin modifications and their function. Cell 128:693–705 (2007) (58) Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes & Development 12:599–606. (59) Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, Li Z, Yao TP, Pestell RG. Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. The Journal of Biological Chemistry 280:16934-41 (2005) (60) Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Science 13:1979-87 (2004) (61) Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nature Reviews Molecular Cell Biology 5:897-907 (2004) (62) Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nature Chemical Biology 6:209-217( 2010 ) (63) Counis MF, Chaudun E, Carreau JP, Courtois Y. Cycloheximide effect on DNA degradation and delta-crystallin synthesis in terminally differentiating lens cells. Biochimica et Biophysica Acta 607:43-52 (1980) (64) Kistler A. Teratogenesis of retinoic acid in rats: susceptible stages and suppression of retinoic acid-induced limb malformations by cycloheximide. Teratology 23:25-31 (1981) (65) Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular ynthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Research 55:2122-8 (1995) (66) Wu W, Alexis N, Chen X, Bromberg P, Peden D. Involvement of mitogen-activated protein kinases and NFkappaB in LPS-induced CD40 expression on human monocytic cells. Toxicology and Applied Pharmacology 228:135-43 (2008) (67) Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clinical Cancer Research 10:8094-104 (2004) (68) Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 26:1182-95 (2005) (69) Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-41 (1997) (70) Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochimica et Biophysica Acta 1813:1978-86 (2011) (71) Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Reviews in Molecular Medicine 10:e19 (2008) (72) Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes & Development 12:3499-511 (1998) (73) David A. Foster Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. Biochim Biophys Acta 1791: 949–955 (2009) (74) Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clinical Cancer Research 18:3603-15 (2012) (75) Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular Cancer Therapeutics 9:1956-67 (2012) (76) Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. Journal of Nuclear Medicine 52:497-500 (2011) (77) Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Basecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3:192-222 (2011) (78) Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Molecular Cell 24:185-97 (2006) (79) Wootz H, Hansson I, Korhonen L, Lindholm D. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Experimental Cell Research 312:1890-8 (2006) (80) Glass JD, Culver DG, Levey AI, Nash NR. Very early activation of m-calpain in peripheral nerve during Wallerian degeneration. Journal of the Neurological Sciences 196:9-20 (2005) (81) Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiological Reviews 83:731-801 (2003) (82) Neumann JT, Diaz-Sylvester PL, Fleischer S, Copello JA. CGP-37157 inhibits the sarcoplasmic reticulum Ca2+ ATPase and activates ryanodine receptor channels in striated muscle. Molecular Pharmacology 79:141-7 (2011) (83) Czyz A, Kiedrowski L. Inhibition of plasmalemmal Na+/Ca2+ exchange by mitochondrial Na+/Ca2+ exchange inhibitor 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one (CGP-37157) in cerebellar granule cells. Biochem Pharmacol 66:2409–2411 (2003) (84) Thu le T, Ahn JR, Woo SH. Inhibition of L-type Ca2+ channel by mitochondrial Na+-Ca2+ exchange inhibitor CGP-37157 in rat atrial myocytes. European Journal of Pharmacology 552:15–19 (2006) (85) Henriksson M, Luscher B: Proteins of the Myc network: essential regulators of cell growth and differentiation. Advances in Cancer Research 68:109–182 (1996) (86) Wootz H, Hansson I, Korhonen L, Lindholm D. XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice. Experimental Cell Research 312:1890-8 (2006) (87) Nesbit CE, Tersak JM, Prochownik EV: MYConcogenes and human neoplastic disease. Oncogene 18:3004–3016 (1999) (88) Wasylishen AR, Penn LZ. Myc: The beauty and the beast. Genes & Cancer 1:532-41 (2010). (89) Swartling FJ. Myc proteins in brain tumor development and maintenance. Upsala Journal of Medical Sciences 117:122-31 (2012). (90) Luscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene 494:145-60 (2012). (91) Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene 18:2942-54 (1999). (92) Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and Prostate Cancer. Genes Cancer 1:617-28 (2010). (93) Croce CM, Erikson J, ar-Rushdi A, Aden D, Nishikura K. Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells. Proceedings of the National Academy of Sciences 81:3170-4 (1984) (94) Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Frontiers in Bioscience 3:d250-68 (1998) (95) Conacci-Sorrell M, Ngouenet C, Eisenman RN. Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell 142:480-93 (2010). (96) Conacci-Sorrell M, Eisenman RN. Post-translational control of Myc function during differentiation. Cell Cycle 10:604-10 (2011). (97) Morgan DO. Principles of CDK regulation. Nature 374:131-134 (1995). (98) Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. The Journal of Biological Chemistry 278:21767-73 (2003). (99) Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer 1:194-202 (2001). (100) McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Research 60:3807-12 (2000) (101) Paul, R. J., Bauer, M. & Pease, W. Vascular smooth muscle: aerobic glycolysis linked to sodium and potassium transport processes. Science 206:1414–16 (1979). (102) Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia 10:198-206 (2008) (103) Mijatovic T, De Neve N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, Kiss R. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Molecular Cancer Therapeutics 7:1285-96 (2008) (104) Mijatovic T, Dewelle J, Quaquebeke EV, Darro F, Kiss R. Cardenolide UNBS1450 induces paraptosis-like cell death in human PC-3 prostate cancer, with marked in vivo anti-tumor activities. American Association for Cancer Research 46: Abstract #3332 (2005) (105) Li Z, Cai T, Tian J, Xie JX, Zhao X, Liu L, Shapiro JI, Xie Z. NaKtide, a Na/K-ATPase-derived peptide Src inhibitor, antagonizes ouabain-activated signal transduction in cultured cells. The Journal of Biological Chemistry 284:21066-76 (2009) (106) HuangYT, Chueh SC, TengCM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 67:727–33 (2004) (107) in H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. The Journal of Biological Chemistry 279:29302–7 (2004) (108) Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H, Miyakawa I. Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Molecular Human Reproduction 11:817-23 (2005) (109) Vlach J., S. Hennecke, K. Alevizopoulos, D. Conti & B. Amati: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. The EMBO Journal 15:6595-6604 (1996) (110) Smith JB, Rozengurt E. Serum stimulates the Na+,K+ pump in quiescent fibroblasts by increasing Na+ entry. Proceedings of the National Academy of Sciences 75:5560-4 (1978) (111) van Zoelen EJ, Mummery CL, Boonstra J, van der Saag PT, de Laat SW. Membrane regulation of the Na+,K+-ATPase during the neuroblastoma cell cycle: correlation with protein lateral mobility. Journal of Cellular Biochemistry 21:77-91 (1983) (112) Panet R, Fromer I, Alayoff A. Rb+ influxes differentiate between growth arrest of cells by different agents. Journal of Membrane Biology 75:219-24 (1983) (113) Alexandrova N, Niklinski J, Bliskovsky V, Otterson GA, Blake M, Kaye FJ, Zajac-Kaye M. The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Molecular and Cellular Biology 15:5188-95 (1995). (114) Niklinski J, Claassen G, Meyers C, Gregory MA, Allegra CJ, Kaye FJ, Hann SR, Zajac-Kaye M. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Molecular and Cellular Biology 20:5276-84 (2000). (115) Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLoS One 7:e29068 (2012) (116) Smith MA, Schnellmann RG. Calpains, mitochondria, and apoptosis. Cardiovascular Research 96:32-7 (2012) (117) Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochemical Pharmacology 67:727-33 (2004) (118) Liu T, Brown DA, O'Rourke B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. Journal of Molecular and Cellular Cardiology 49:728-36 (2010). (119) Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. Journal of Urology 166:1937-42 (2001) (120) Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLoS One 7:e29068 (2012) (121) McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59:4291-6 (1999) | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61575 | - |
dc.description.abstract | 強心內酯配糖體衍生物Reevesioside A,是從台灣梭羅木(Reevesia Formosana)的根部萃取而來,從sulforhodamine B assay偵測細胞的生長,發現Reevesioside A顯著的抑制荷爾蒙不反應型前列腺癌細胞株PC-3及DU-145的生長,並與濃度呈正向關係,其GI50分別為21及14 nM。接著使用Reevesioside A處理 PC-3細胞,做更深入的抗癌機制探討。使用流式細胞儀分析CFSE staining的方法,也證實了reevesioside A所造成的生長抑制作用。對於細胞週期的分析,則是先以高濃度thymidine處理的方法,使細胞週期同步化,結果顯示Reevesioside A會引起細胞停留在G1期,也造成Sub-G1期細胞族群增加。利用西方墨點法觀察細胞週期上游調控者c-Myc及細胞週期調控者cyclin D1、cyclin E、phospho-RbSer807/811蛋白質表現量,分別於加藥處理二小時及六小時後,發現其表現量顯著的減少,與早期G1期停滯結果相符合。利用轉殖技術將Myc過量持續表現,發現可以有效的逆轉Reevesioside A引起的cyclin D1、cyclin E、phospho-RbSer807/811蛋白質表現量減少的現象。此外,Reevesioside A可以顯著的抑制AKTThr308及AKTSer473的磷酸化(活化)作用,但以轉殖技術來持續活化AKT (myristylated-AKT),並無法抑制的作用。而Reevesioside A活化了mTOR途徑,如增加phospho-mTORSer2448、phospho-p70S6KThr389及phospho-GSK-3βSer9蛋白質表現量。隨著Reevesioside A處理時間越久,發現可以引起越多的粒線體膜電位喪失的現象。值得注意的是,傳統強心配糖體類的藥物具有心臟毒性,而Reevesioside A對於大鼠心肌母細胞株H9c2,則不具有毒性。總結來說,Reevesioside A透過抑制Myc、減少cyclin D1 及 cyclin E的蛋白質表現量,最終造成荷爾蒙不反應型前列腺癌細胞停滯於細胞週期的G1期,而抑制其生長及造成細胞作用,故具有後續開發潛力。 | zh_TW |
dc.description.abstract | Reevesioside A, a cardenolide glycoside isolated from the roots of Reevesia Formosana, induced a concentration-dependent inhibition of cell proliferation in human hormone-refractory prostate cancers PC-3 and DU-145 cells by sulforhodamine B assay. The GI50 values are 21 and 23 nM, respectively. The submaximal concentration of 50 nM reevesioside A was used for the mechanism study in PC-3 cells accordingly. Flow cytometric analysis of CFSE staining confirmed that reevesioside A induced an anti-proliferative activity. The progression of cell cycle was detected using thymidine block to synchronize cells. The data demonstrated that reevesioside A induced a profound G1-phase arrest and an increased subG1 phase of the cell cycle . The detection of cell cycle regulators revealed that reevesioside A induced a dramatic down-regulation of c-Myc, cyclin D1, cyclin E and phospho-RbSer807/811, which was well correlated with the induction of G1 phase arrest. The overexpression of Myc (e.g., constitutive Myc activation) inhibited reevesioside A-induced downregulation of cyclin D1, cyclin E and phospho-RbSer807/811 expression. Moreover, reevesioside A significantly inhibited both phospho-AKTSer473 and phospho-AKTThr308. The overexpression of myristylated- AKT (e.g., constitutive AKT activation) could not inhibit reevesioside A-induced effect. Although reevesioisdie A induced the loss of MMP in PC-3 cells, it also resulted in an activation of mTOR signaling pathway, including the increase of the protein levels of phospho-mTORSer2448, phospho-p70S6KThr389 and phospho-GSK-3βSer9. Of note, reevesioside A showed preferential selectivity against prostate cancer cells other than cardiac H9c2 cells. It is of particular significance because traditional cardiac glycosides always show cardiac toxicity. In contrast, reevesioside A did not cause toxic effect in cardiac cells. In conclusion, the data suggest that reevesioside A displays anticancer activity through the down-regulation of c-Myc, cyclin D1 and cyclin E which cause G1 phase arrest of the cell cycle and, ultimately, apoptosis in human hormone-refractory prostate cancers cells. The data also indicate the potential of reevesioside A for further development. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:06:17Z (GMT). No. of bitstreams: 1 ntu-102-R00423018-1.pdf: 3878795 bytes, checksum: 25bdf4bce6cd1a0fdb5ee7c6a1e53c20 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 口試委員會審定書 I
致謝 II 縮寫表……………………………………………………………….. III 中文摘要……………………………………………………….…… V 英文摘要……………………………………………………………VI 目錄…………………………………………………………………VIII 圖表目錄...…………………………………………………………X 研究動機…………………………………………………………… 1 文獻回顧…………………………………………………………… 2 實驗材料…………………………………………………………… 15 實驗方法…………………………………………………………… 16 1.細胞培養…………………………………………………………. 16 2.細胞計數…………………………………………………………. 17 3.抑制細胞生長測定法-SRB assay、MTT assay……………….. 17 4.流式細胞儀………………………………………………………. 18 A.偵測細胞週期…………………………………………………… 18 B.偵測細胞內鈣離子含量………………………………………… 18 C.偵測氧化自由基的含量………………………………………… 18 D.偵測細胞增生…………………………………………………… 19 E. Early S-phase synchronization - Thymidine block…………… 19 F. 偵測粒線體膜電位…………………………………………….. 20 5.蛋白質萃取與定量……………………………………………… 20 6.西方墨點法……………………………………………………… 21 7. Starvation assay…………………………………………………. 23 8. PCR…………………………………………………………….... 23 9. 共同免疫沉澱法(co-Immunoprecipitation,coIP)………….. 25 10. 細胞轉染(Transfection)…………………………………….. 26 11. 組蛋白去乙醯酶顯色活性試驗…...…………………………… 26 12資料統計與分析…………………………………………………. 27 實驗結果…………………………………………………………….. 28 討論………………………………………………………………….. 34 結論………………………………………………………………….. 41 圖表………………………………………………………………….. 42 參考資料…………………………………………………………….. 70 | |
dc.language.iso | zh-TW | |
dc.title | 強心內酯配醣體衍生物在人類荷爾蒙不依賴型前列腺癌細胞之抗癌作用機轉探討 | zh_TW |
dc.title | Study of Anticancer Mechanism of Cardenolide Glycoside Derivatives against Human Hormone-Refractory Prostate Cancers | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊家榮(Chia-Ron Yang),許麗卿(Lih-Ching Hsu),黃聰龍(Tsong-Long Hwang),蕭哲志(George Hsiao) | |
dc.subject.keyword | prostate cancer,G1 phase arrest,Myc,Cardenolide,Reevesioside A, | zh_TW |
dc.relation.page | 84 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 3.79 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。